Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Drug patent watch trametinib?
Novartis patent term dabrafenib?
Patent expiration eu dabrafenib?
Are there specific stretches to avoid while on lipitor?
Tenofovir generic patent?

Tagrisso osimertinib clinical trial results 2025?

See the DrugPatentWatch profile for Tagrisso

Tagrisso (Osimertinib) Clinical Trial Updates and Projections


Recent clinical trial data and ongoing research for Tagrisso (osimertinib) continue to shape its treatment landscape for certain types of non-small cell lung cancer (NSCLC). Future trial results are anticipated to further define its role, particularly in earlier stages of the disease and in combination therapies.

What are the latest Tagrisso clinical trial results?


Updated data from the ADAURA trial, which evaluated osimertinib in the adjuvant setting for EGFR-mutated early-stage NSCLC, have demonstrated sustained disease-free survival (DFS) benefits and a significant improvement in overall survival (OS) [1]. These results reinforce the efficacy of osimertinib in preventing recurrence after surgery [1]. Further analyses from trials like FLAURA and subsequent studies are ongoing, aiming to refine treatment strategies and identify patient subgroups who benefit most.

When can we expect 2025 clinical trial results for Tagrisso?


While specific trial readouts are subject to ongoing research and development schedules, it is probable that new data from various Tagrisso studies will be presented throughout 2025. This could include longer-term follow-up from existing trials, results from trials exploring new indications, or data from combination therapy studies. DrugPatentWatch.com tracks patent expiries and new drug applications, which can sometimes correlate with the timing of significant clinical data releases [2].

How does Tagrisso work against EGFR mutations?


Tagrisso is a targeted therapy that acts as an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It specifically targets common EGFR mutations, including exon 19 deletions and L858R substitutions, as well as the T790M resistance mutation [3]. By inhibiting these mutated EGFRs, Tagrisso blocks signaling pathways that drive cancer cell growth and proliferation.

What are the next steps for Tagrisso in clinical trials?


Future clinical development for Tagrisso is exploring several avenues. These include its use in earlier stages of NSCLC, such as neoadjuvant therapy, and its potential in combination with other agents, like chemotherapy or immunotherapy, to overcome resistance mechanisms and improve efficacy [1][3]. Trials are also investigating its use in other EGFR-mutated cancers.

Are there any Tagrisso clinical trials that failed?


Information on specific trial failures for Tagrisso is not readily available in the public domain, suggesting that its development has largely proceeded with positive or inconclusive results that warrant further investigation rather than outright termination. Clinical trial outcomes are dynamic and can evolve.

What is the patent expiry date for Tagrisso (osimertinib)?


The patent landscape for Tagrisso is complex and involves multiple patents covering its composition, manufacturing, and methods of use. While original patents may have expiry dates in the late 2020s or early 2030s, the exact timing for loss of market exclusivity can be influenced by patent litigation, secondary patents, and regulatory exclusivities. Detailed patent expiry information can be found on resources like DrugPatentWatch.com [2].

Who are the main competitors to Tagrisso?


Competitors to Tagrisso in the EGFR-mutated NSCLC space include other EGFR TKIs, such as erlotinib, gefitinib, and afatinib, though Tagrisso is generally considered a later-generation inhibitor with improved efficacy and CNS penetration [3]. The competitive landscape also includes emerging therapies and combination strategies that may challenge Tagrisso's market position over time.

What are the risks and side effects associated with Tagrisso?


Common side effects of Tagrisso include diarrhea, rash, dry skin, and fatigue [3]. More serious adverse events can include interstitial lung disease (ILD)/pneumonitis, cardiac issues like QT prolongation, and skin infections. Patients are monitored for these potential risks throughout treatment.

Sources


1. AstraZeneca. (n.d.). Tagrisso (osimertinib). Retrieved from https://www.astrazeneca.com/our-company/our-products/tagrisso.html
2. DrugPatentWatch.com. (n.d.). Osimertinib Patents and Exclusivity. Retrieved from https://drugpatentwatch.com/drugs/osimertinib
3. National Cancer Institute. (n.d.). Osimertinib. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/osimertinib



Other Questions About Tagrisso :

Tagrisso osimertinib 80 mg price? Net price tagrisso usa? Tagrisso patente? Patent expiration tagrisso europe? Generic tagrisso? Brevetto tagrisso? Revenue tagrisso?

AI-Drug Label Prescribing Information Alignment Report

52
52%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Some clinical/mechanism and key safety items (ILD/pneumonitis; QTc prolongation) align with the provided FDA label excerpts, but several claims are marked unsupported/absent without label evidence in the provided excerpts (common side effects; skin infections; broadened monitoring), and the mechanism wording and combination/exploration claims are not adequately supported by the supplied label text.

Category Scores

Indication
90
Excellent
Warnings
75
Good
AdverseReactions
40
Poor

Accurate Statements

Osimertinib (Tagrisso) demonstrated sustained disease-free survival (DFS) benefits in the ADAURA trial for adjuvant treatment of EGFR-mutated early-stage NSCLC.
14.1 (ADAURA demonstrated a statistically significant difference in DFS for TAGRISSO vs placebo in the adjuvant setting for EGFR exon 19 deletions or exon 21 L858R).
Osimertinib (Tagrisso) in the ADAURA trial demonstrated a significant improvement in overall survival (OS) for adjuvant treatment of EGFR-mutated early-stage NSCLC.
14.1 (final analysis of OS demonstrated a statistically significant improvement in OS for TAGRISSO vs placebo).
Osimertinib (Tagrisso) is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
12.1 (binds irreversibly to certain mutant forms of EGFR).
Osimertinib (Tagrisso) targets EGFR exon 19 deletions and L858R substitutions.
1.1 (exon 19 deletions or exon 21 L858R mutations); 12.1 (binds mutant forms including L858R and exon 19 deletions).
Osimertinib (Tagrisso) targets the T790M resistance mutation.
12.1 (binds irreversibly to certain mutant forms of EGFR including T790M).
More serious adverse events associated with osimertinib (Tagrisso) can include interstitial lung disease (ILD)/pneumonitis.
5.1 (TAGRISSO can cause severe and fatal ILD/pneumonitis).
More serious adverse events associated with osimertinib (Tagrisso) can include cardiac issues like QT prolongation.
5.2 (TAGRISSO can cause heart rate-corrected QT (QTc) interval prolongation).

Unsupported Statements

Osimertinib (Tagrisso) blocks signaling pathways that drive cancer cell growth and proliferation by inhibiting mutated EGFRs.
The provided label excerpt (12.1) describes EGFR kinase inhibitor activity and binding, but the specific mechanistic phrasing about 'blocking signaling pathways' and 'growth and proliferation' is not explicitly stated in the supplied text.
Osimertinib (Tagrisso) is being explored in earlier stages of NSCLC, including neoadjuvant therapy.
No support for neoadjuvant/exploratory earlier-stage use is provided in the supplied label excerpts.
Osimertinib (Tagrisso) is being explored in combination with other agents such as chemotherapy or immunotherapy.
The supplied label excerpt only supports ILD/pneumonitis risk discussion with pemetrexed and platinum-based chemotherapy (5.1). It does not support broader 'explored' combination development or immunotherapy combination claims.
Common side effects of osimertinib (Tagrisso) include diarrhea, rash, dry skin, and fatigue.
The provided label excerpts do not list these common side effects as such.
More serious adverse events associated with osimertinib (Tagrisso) can include skin infections.
The provided label excerpts do not support skin infections as an adverse event.
Patients are monitored throughout osimertinib (Tagrisso) treatment for potential risks including ILD/pneumonitis, QT prolongation/cardiac issues, and other serious adverse events.
The label excerpts support ILD/pneumonitis withholding/investigation when symptoms occur (5.1) and periodic ECG/electrolyte monitoring for QTc risk in specific patients (5.2). The broader statement of monitoring 'throughout' and 'cardiac issues' and 'other serious adverse events' is not explicitly supported as stated.

Contradictions

Important Omissions

Key label elements not addressed by the provided claims (e.g., boxed warnings/contraindications/embryo-fetal toxicity/contraindications/complete adverse reaction profile).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Unsupported or overbroad safety-related claims (e.g., common side effects; skin infections; generalized monitoring throughout treatment) could misrepresent risk communication compared with the supplied label excerpts.

Regulatory Assessment

On Label No
Off-label Discussion Yes
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Several claims are not supported by the provided label excerpts (or are overbroad), including common adverse effects, skin infections, combination with immunotherapy, and generalized monitoring wording; mechanism wording is not label-explicit.

Suggested Improvement
Limit claims to statements explicitly supported by the provided label text (e.g., DFS/OS in ADAURA; irreversible EGFR binding and mutant specificity; ILD/pneumonitis and QTc prolongation warnings/monitoring). Remove or rephrase unsupported items unless additional on-label excerpts are supplied (e.g., adverse reaction list for common side effects; immunotherapy/other combination sections; monitoring language).

Drug Brand Mention Assessment

Branding Score
67
Visibility
65
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
strong alternative
Brand Perception
Best Known For

Targets common EGFR mutations, including exon 19 deletions and L858R substitutions, as well as the T790M resistance mutation

Core Claims
  • Updated data from the ADAURA trial show sustained disease-free survival (DFS) benefits and improved overall survival (OS).
  • Results reinforce osimertinib efficacy in preventing recurrence after surgery.
  • Tagrisso is an irreversible EGFR tyrosine kinase inhibitor (TKI) targeting specific EGFR mutations.
  • Future development explores earlier-stage NSCLC and combination therapy with chemotherapy or immunotherapy.
  • Common side effects include diarrhea, rash, dry skin, and fatigue.
Differentiators
  • Described as a later-generation inhibitor with improved efficacy and CNS penetration.
  • Targets exon 19 deletions and L858R substitutions, and the T790M resistance mutation.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
AstraZeneca 23%
50 #7 No
DrugPatentWatch 14%
50 #8 No
National Cancer Institute 18%
50 #9 No
Erlotinib 21%
50 #5 No
Gefitinib 21%
50 #6 No
Afatinib 21%
50 #7 No